AANS/CNS Liaison. AAN Liaison. CLINICAL STATEMENTS AND GUIDELINES Kleindorfer Appendix 1. Writing Group Relationships With Industry and Other Entities (Relevant): 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack Writing group member Employment Research grant Other research support Speakers bureau/ honoraria Expert witness Ownership interest Consultant/ advisory board Other Dawn O. Kleindorfer University of Michigan NIH (epidemiology of stroke) None None None None None None Amytis Towfighi University of Southern California NIH/NINDS (secondary stroke prevention trial) None None None None None None Seemant Chaturvedi School of Medi- cine, University of Maryland Boehringer-Ingelheim (grant support)* None None None None None NINDS (executive committee Kevin M. Cockroft (AANS/CNS WG Represen- tative) Penn State Hershey Medical Center Medtronic (PI for multi-institution study) ; Nico Corp (PI for multi-institu- tion study) Intersocietal Accreditation Commission (Board of Directors)* None None Actuated Medical* Medtronic ; Minnetronix* None Jose Gutierrez Columbia University Medical Center NIH (PI in research grant) None None Hanna, Campbell & Powell, LLP*; Heidell, Pittoni, Murphy & Bach, LLP*; Aaronson Rappaport*; Johnson, Graffe, Keay, Moniz & Wick*; Luca Law, PLLC* None None None Hooman Kamel Weill Cornell Medical College BMS (BMS provides in-kind study drug [apixaban/aspirin/placebo] for ARCADIA trial, of which he is co-PI) ; Boehringer Ingelheim (Endpoint Adjudication Committee for a trial of empagliflozin) ; Medtronic (unpaid Steering Committee member of STROKE AF Trial)*; NIH/ NINDS (co-PI of ARCADIA trial, PI of LANTERN observational study of atrial cardiopathy and racial disparities in stroke, coinvestigator of a stroke policy simula- tion model project) ; Roche Diagnostics (Roche Diagnostics provides in-kind study assay kits [NT-proBNP] for ARCADIA trial, of which he is co-PI) ; Clinical Endpoint Adjudication Committee for an RCT related to empagliflozin, a diabetes drug. The trial sponsor is Boehringer- Ingelheim. 